GLP-1 Drugs Are About to Destroy Medicare Costs

1. 1. Medicare's upcoming coverage of GLP-1 weight loss drugs starting July 2026 presents a significant financial challenge.
2. 2. Medicare Part D spending on GLP-1 drugs already surged to $27.5 billion in 2024.
3. 3. CMS created new programs to cover GLP-1s for weight loss, bypassing existing federal law.
4. 4. GLP-1 drugs are moderately expensive, chronic, and target a mass market of millions.
5. 5. Medicare's design for catastrophic events struggles with chronic, mass-market preventive therapies like GLP-1s.